Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study

BACKGROUND: The purpose of this retrospective study was to evaluate the survival outcomes of pembrolizumab (PEM) plus enzalutamide (ENZ) versus PEM alone in selected populations of men with previously untreated metastatic castration-resistant prostate cancer (mCRPC) harbouring programmed cell death...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Huanyi, Liu, Qilong, Zeng, Xianshang, Yu, Weiguang, Xu, Guixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045189/
https://www.ncbi.nlm.nih.gov/pubmed/33849473
http://dx.doi.org/10.1186/s12885-021-08156-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045189/
https://www.ncbi.nlm.nih.gov/pubmed/33849473
http://dx.doi.org/10.1186/s12885-021-08156-1

Ejemplares similares